Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
Axfors, C.; Pezzullo, A. M.; Contopoulos-Ioannidis, D.; Apostolatos, A.; Ioannidis, J. P. A.
Show abstract
BackgroundCOVID-19 exhibits a steep age gradient of infection fatality rate. There has been debate about whether extra protection of elderly and other vulnerable individuals (precision shielding) is feasible, and, if so, to what extent. MethodsWe used systematically retrieved data from national seroprevalence studies conducted in the pre-vaccination era. Studies were identified through SeroTracker and PubMed searches (last update May 17, 2022). Studies were eligible if they targeted representative general populations without high risk of bias. Seroprevalence estimates were noted for children, non-elderly adults, and elderly adults, using cut-offs of 20, and 60 years (or as close to these ages, if they were not available). ResultsThirty-eight national seroprevalence studies from 36 different countries were included in the analysis. 26/38 also included pediatric populations. 25/38 studies were from high-income countries. The median ratio of seroprevalence in the elderly versus non-elderly adults (or non-elderly in general, if pediatric and adult population data were not offered separately) was 0.90-0.95 in different analyses with large variability across studies. In 5 studies (all of them in high-income countries), there was significant protection of the elderly with ratio <0.40. The median was 0.83 in high-income countries and 1.02 in other countries. The median ratio of seroprevalence in children versus adults was 0.89 and only one study showed a significant ratio of <0.40. ConclusionPrecision shielding of elderly community-dwelling populations before the availability of vaccines was feasible in some high-income countries, but most countries failed to achieve any substantial focused protection of this age group. summary38 COVID-19 nationally representative seroprevalence studies conducted before vaccination campaigns were systematically identified. Median seroprevalence ratio in elderly versus non-elderly adults was 0.90-0.95, indicating no generally achieved precision shielding of elderly. In 5 studies, substantial protection (ratio <0.40) was observed.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview 95%
- Sex differences in the mortality rate for coronavirus disease 2019 compared to other causes of death 90%
- The methodologies to assess the effects of non-pharmaceutical interventions during COVID-19: a systematic review 89%
Similar papers in this journal
- Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality 94%
- COVID-19 among migrants, refugees, and internally displaced persons: systematic review, meta-analysis and qualitative synthesis of the global empirical literature 91%
- SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine 91%
Similar papers in this journal
- Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Dec 2021 91%
- Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial 91%
- Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults 91%
Similar papers in this journal
- Susceptibility and infectiousness of SARS-CoV-2 in children versus adults, by variant (wild-type, Alpha, Delta): a systematic review and meta-analysis of household contact studies 93%
- Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study 93%
- Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany 93%
Similar papers in this journal
- Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023 93%
- mRNA vaccines effectiveness against COVID-19 hospitalizations and deaths in older adults: a cohort study based on data-linkage of national health registries in Portugal 93%
- Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.